Kao L C, Durand D J, Nickerson B G
Division of Neonatology, Children's Hospital, Oakland, CA 94609.
Pediatr Pulmonol. 1989;6(2):74-80. doi: 10.1002/ppul.1950060204.
We evaluated the individual and combined effects of an inhaled beta-adrenergic agent (metaproterenol) and an inhaled anticholinergic agent (atropine) on the pulmonary function of infants with bronchopulmonary dysplasia. In this randomized, double-blind study we studied 15 infants at a mean postnatal age of 15.8 weeks (range 4-28 weeks). On 4 successive days, pulmonary function tests were measured before and after a single treatment with one of the following four aerosols: placebo, metaproterenol, atropine, and combined metaproterenol and atropine. Following treatment with metaproterenol, atropine, and combined metaproterenol and atropine, airway resistance and maximal expiratory flow at functional residual capacity improved significantly when compared with baseline. Pulmonary function values returned toward baseline by 3 hours after the treatments. We found no significant differences between the effects of metaproterenol and atropine and were unable to show any synergy of the two agents.
我们评估了吸入型β-肾上腺素能药物(间羟异丙肾上腺素)和吸入型抗胆碱能药物(阿托品)对支气管肺发育不良婴儿肺功能的单独及联合作用。在这项随机双盲研究中,我们研究了15名平均出生后15.8周(范围4 - 28周)的婴儿。在连续4天里,在使用以下四种气雾剂之一进行单次治疗前后测量肺功能测试:安慰剂、间羟异丙肾上腺素、阿托品以及间羟异丙肾上腺素与阿托品联合使用。在用间羟异丙肾上腺素、阿托品以及间羟异丙肾上腺素与阿托品联合使用治疗后,与基线相比,气道阻力和功能残气量时的最大呼气流量显著改善。治疗后3小时肺功能值恢复至基线水平。我们发现间羟异丙肾上腺素和阿托品的作用之间没有显著差异,并且未能显示出这两种药物之间有任何协同作用。